Neurogenic Mechanisms of Antiobesity Medications: Insights and Future Directions

Overview

Antiobesity medications (AOMs), particularly GLP-1 receptor agonists like liraglutide and semaglutide, not only reduce food intake but also influence adult hypothalamic neurogenesis (hAN). Recent studies demonstrate that AOMs preserve hypothalamic neural stem cells and promote neuronal survival under high-fat diet conditions, suggesting a neurogenic component to their therapeutic effects.

Background

Obesity management has increasingly relied on AOMs, with prescriptions doubling since 2018, driven by agents such as semaglutide and tirzepatide. These drugs primarily act by enhancing satiety through hypothalamic pathways, notably targeting neurons in the medial basal hypothalamus (MBH). The MBH contains adult neural stem cells (htNSCs) capable of generating new neurons that regulate energy homeostasis. Understanding how AOMs affect hAN could reveal additional mechanisms contributing to their efficacy and long-term benefits.

Data Highlights

Experimental data in mice exposed to high-fat diets showed that liraglutide and a lipidized prolactin-releasing peptide analog (LiPR) reduced activation and proliferation of htNSCs and hypothalamic progenitors. Both AOMs decreased cell proliferation in the MBH parenchyma under physiological and diet-induced obesity conditions. Additionally, AOM treatment increased the survival of newly generated MBH neurons during high-fat diet exposure, indicating neuroprotective effects beyond appetite suppression.

Key Findings

• AOMs reduce proliferation and increase quiescence of hypothalamic neural stem cells and progenitors, potentially preserving adult neurogenesis during obesity.
• Semaglutide crosses the blood–brain barrier via tanycytes, which serve as hypothalamic gatekeepers and adult neural stem cells.
• AOMs promote survival of adult-born neurons in the MBH under high-fat diet conditions, suggesting neuroprotective properties.
• Treatment with AOMs does not alter the proportion of anorexigenic POMC+ neurons, indicating effects may be mediated through neuronal connectivity and function rather than subtype ratios.
• Adult hypothalamic neurogenesis may contribute to the anorexigenic effects of AOMs and protection against diet-induced obesity.
• Further studies are needed to establish whether hypothalamic neurogenesis is necessary for the efficacy of AOMs, paralleling neurogenic hypotheses in depression research.

Clinical Implications

These findings highlight a potential neurogenic mechanism underlying the efficacy of AOMs, suggesting that preserving or enhancing hypothalamic neurogenesis could be a therapeutic target in obesity management. Clinicians should consider that benefits of AOMs may extend beyond appetite suppression to include neuroprotection and hypothalamic circuit remodeling, which might contribute to sustained weight control. Future therapies might be developed to specifically modulate adult hypothalamic neurogenesis to improve obesity outcomes.

Conclusion

Antiobesity medications exert complex effects on hypothalamic neurogenesis, promoting neural stem cell preservation and neuronal survival that may support their anorexigenic actions. Establishing a neurogenic hypothesis of obesity treatment could open new avenues for understanding and enhancing therapeutic strategies.

References

1. Au et al. 2023 -- Review on GLP-1 receptor agonists and neuroprotection
2. Malberg et al. 2000 -- Antidepressants increase hippocampal neurogenesis
3. Santarelli et al. 2003 -- Neurogenesis required for antidepressant efficacy
4. Kokoeva et al. 2005 -- Hypothalamic neurogenesis and obesity
5. Recent experimental study (2023) -- Effects of liraglutide and LiPR on hypothalamic neurogenesis